Umbrella review of meta-analyses finds no significant suicidal risk from GLP-1 receptor agonist therapy | Research

The takeaway

First umbrella review integrating all meta-analytic evidence on GLP-1RA suicidality finds no significant association, though methodological limitations and heterogeneous definitions across studies warrant continued surveillance.

No suicidal risk signal
The highest level of evidence synthesis finds no significant association between GLP-1 drugs and suicidality, though continued monitoring is recommended

What the researchers found

No significant association between GLP-1RA therapy and suicidality across integrated meta-analytic evidence. Methodological limitations: heterogeneous definitions, inconsistent reporting, small event numbers. Ongoing surveillance recommended.

Why it matters

Suicidality concerns have threatened GLP-1 drug adoption. This highest-level evidence synthesis provides reassurance while appropriately acknowledging study limitations.

How the study worked

First umbrella review (review of meta-analyses) on GLP-1RA and suicidality. Systematic search of MedLine, PubMed, PsychInfo, Web of Science, Science Direct, Sage, Wiley, Springer.

What this study cannot tell us

Umbrella reviews depend on quality of underlying meta-analyses. Suicidal events are rare and may be underreported. Post-marketing data may differ from trial data.

How to read the evidence

Umbrella review—highest evidence synthesis level. Reassuring finding but acknowledges limitations of underlying data.

When this study was published

Published in 2025.

The bigger picture

This addresses one of the most sensitive safety questions about GLP-1 drugs. While reassuring, the finding highlights the need for better adverse event reporting and standardized definitions in future trials.

Questions still open

Should psychiatric screening be recommended before GLP-1 therapy?
Are specific GLP-1 drugs associated with more psychiatric events?
Will dedicated psychiatric safety trials be conducted?

Common questions

Do GLP-1 drugs cause suicidal thoughts?

This umbrella review—the most comprehensive evidence analysis possible—found no significant link between GLP-1 drugs and suicidal ideation or behavior. While reassuring, the review notes that better reporting of mental health events in future studies would strengthen this conclusion.

Should I worry about mental health effects of semaglutide?

Based on the best available evidence, GLP-1 drugs do not appear to increase suicidal risk. However, as with any medication, you should report any mood changes to your healthcare provider. The review recommends continued safety monitoring as more people use these drugs.

Read the original research

Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence.

Healthcare (Basel, Switzerland), 13(22)

View on PubMed ↗Publisher’s paper ↗

Citation

Ștefănescu, Cristina; Bratu, Elena Alexandra; Pelin, Ana Maria; Boroi, Denisa; Crecan-Suciu, Bianca Daniela; Ștefănescu, Victorița. (2025). Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence.. Healthcare (Basel, Switzerland), 13(22). https://doi.org/10.3390/healthcare13222958